Context Therapeutics Inc. (NASDAQ: CNTX) Stock Information | RedChip

Context Therapeutics Inc. (NASDAQ: CNTX) Listen to this Section


$2.61
-0.0500 ( -1.88% ) 88.7K

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Market Data


Open


$2.61

Previous close


$2.66

Volume


88.7K

Market cap


$195.75M

Day range


$2.54 - $2.70

52 week range


$0.77 - $2.75

Insider Ownership Transactions

Total Amount Purchased: -932,202.00 | $ -2,433,047.22

Date Type Amount Purchased Purchaser
2024-08-01 Sale -202170.00 Dansky Ullmann Claudio
2024-06-14 Sale -50000.00 BERMAN RICHARD J
2024-06-14 Sale -25000.00 West Linda
2024-06-14 Sale -25000.00 Kantoff Philip W.
2024-06-14 Sale -25000.00 Stacey Jennifer Evans
2024-03-22 Sale -291402.00 Lehr Martin A.
2024-03-22 Sale -153515.00 Levit Alex C.
2024-03-22 Sale -160115.00 Minai-Azary Jennifer Lynn

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 59 Aug 07, 2024
3 Insider transactions 2 Aug 01, 2024
4 Insider transactions 1 Aug 01, 2024
def Proxies and info statements 4 Jul 24, 2024
pre Proxies and info statements 4 Jul 12, 2024
8-k 8K-related 46 Jul 10, 2024
8-k 8K-related 13 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.